Evidence map›Paper›PMID 27230990›Full record

SynthesisObesity reviews : an official journal of the International Association for the Study of Obesity2016

A systematic review of commercial weight loss programmes' effect on glycemic outcomes among overweight and obese adults with and without type 2 diabetes mellitus.

Z W Chaudhry, R S Doshi, A K Mehta, D K Jacobs, R M Vakil, C J Lee, S N Bleich, R R Kalyani, J M Clark, K A Gudzune

Registry-linked trialAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Obesity reviews : an official journal of the International Association for the Study of Obesity, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06363747 (The Medically Reproducing Bariatric Surgery), which is not on this map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06363747 phase2 / phase3active not recruitingnot on this mapstarted 2024, after this paper: background citation

The Medically Reproducing Bariatric Surgery (MRB) II Study: SEMAGLUTIDE Followed by OPTIFAST in Veterans With Type 2 Diabetes

TypeinterventionalSponsorDurham VA Medical CenterRan2024 to 2025Enrolled50ConditionsType 2 Diabetes, ObesityArmsVery Low Calorie Diet
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Treatment of Obesity in Patients With Diabetes.Diabetes spectrum : a publication of the American Diabetes Association · 2017
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Z W ChaudhryThe Johns Hopkins University School of Medicine, Baltimore, MD, USA.
R S DoshiThe Johns Hopkins University School of Medicine, Baltimore, MD, USA.
A K MehtaThe Johns Hopkins Bayview Medical Center, Baltimore, MD, USA.
D K JacobsThe University of Maryland School of Medicine, Baltimore, MD, USA.
R M VakilThe Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
C J LeeThe Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-0824-0207
S N BleichThe Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
R R KalyaniThe Johns Hopkins University School of Medicine, Baltimore, MD, USA.
J M ClarkThe Johns Hopkins University School of Medicine, Baltimore, MD, USA.
K A GudzuneThe Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Funding

Research BaseP30DK072488 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · PI MITCHELL, BRAXTON D · 2005 to 2019
$17.3M
JHU-UMD Diabetes Research CenterP30DK079637 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI AHIMA, REXFORD S. · 2013 to 2017
$9.7M
Institute for Clinical and Translational ResearchTL1TR001078 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$1.9M
Reducing obesity among public housing residents: an ecological approachK23HL116601 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI GUDZUNE, KIMBERLY ANNE · 2013 to 2017
$778k
Racial Disparities in Physician Practice Patterns and Self-Management of ObesityK01HL096409 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI BLEICH, SARA NAOMI · 2009 to 2013
$699k
Glucose Insulin and Muscle LossK23DK093583 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI KALYANI, RITA R · 2012 to 2015
$635k
NCATS NIH HHS TL1 TR001078NHLBI NIH HHS K01 HL096409NHLBI NIH HHS K23 HL116601NIDDK NIH HHS K23 DK093583NIDDK NIH HHS P30 DK072488NIDDK NIH HHS P30 DK079637
6 · The paper itself

Abstract

objectiveWe examined the glycemic benefits of commercial weight loss programmes as compared with control/education or counselling among overweight and obese adults with and without type 2 diabetes mellitus (T2DM).

methodsWe searched MEDLINE, Cochrane Database of Systematic Reviews, and references cited by individual programmes. We included randomized controlled trials of ≥12 weeks duration. Two reviewers extracted information on study design, population characteristics, interventions, and mean changes in haemoglobin A1c and glucose.

resultsWe included 18 randomized controlled trials. Few trials occurred among individuals with T2DM. In this population, Jenny Craig reduced A1c at least 0.4% more than counselling at 12 months, Nutrisystem significantly reduced A1c 0.3% more than counselling at 6 months, and OPTIFAST reduced A1c 0.3% more than counselling at 6 months. Among individuals without T2DM, few studies evaluated glycemic outcomes, and when reported, most did not show substantial reductions. DISCUSSION: Few trials have examined whether commercial weight loss programmes result in glycemic benefits for their participants, particularly among overweight and obese individuals without T2DM. Jenny Craig, Nutrisystem and OPTIFAST show promising glycemic lowering benefits for patients with T2DM, although additional studies are needed to confirm these conclusions. © 2016 World Obesity.

Indexed as

Weight Reduction ProgramsBlood GlucoseDiabetes Mellitus, Type 2Diet, ReducingExerciseHumansObesityOverweightRandomized Controlled Trials as TopicRisk AssessmentTreatment OutcomeBlood GlucoseCommercial weight lossglucosehaemoglobin A1ctype 2 diabetes mellitus

Identifiers

PMID27230990
PMCPMC5512172

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.